|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.20 CHF | -0.91% |
|
-6.55% | -0.91% |
| 01-13 | Basilea Pharmaceutica Ltd. Partners INCATE for Antifungal Innovation | CI |
| 01-13 | Basilea Pharmaceutica Signs Up as Industry Partner for INCATE | MT |
| Capitalization | 666M 830M 715M 620M 1.15B 75.3B 1.24B 7.66B 3.02B 35.92B 3.11B 3.05B 131B | P/E ratio 2025 * |
17.3x | P/E ratio 2026 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise value | 592M 738M 636M 552M 1.03B 66.98B 1.1B 6.81B 2.69B 31.95B 2.77B 2.71B 117B | EV / Sales 2025 * |
2.67x | EV / Sales 2026 * | 2.1x |
| Free-Float |
91.97% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -0.91% | ||
| 1 week | -6.55% | ||
| Current month | -0.91% | ||
| 1 month | +1.88% | ||
| 3 months | +12.56% | ||
| 6 months | -0.55% | ||
| Current year | -0.91% |
| 1 week | 53.5 |  | 58 |
| 1 month | 51.6 | | 58.4 |
| Current year | 51.6 | | 58.4 |
| 1 year | 37.5 | | 59.7 |
| 3 years | 32 | | 59.7 |
| 5 years | 29.55 | | 61.95 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 18/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 09/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 30/04/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Domenico Scala
CHM | Chairman | 60 | 20/04/2016 |
Thomas Werner
BRD | Director/Board Member | 70 | 28/11/2011 |
| Chairman | 71 | 08/04/2013 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.91% | -6.55% | +34.49% | +4.03% | 830M | |
| -0.89% | +1.01% | +0.87% | +12.27% | 48.93B | |
| -1.49% | -1.95% | +20.43% | +7.29% | 40.48B | |
| -0.03% | +0.09% | +60.98% | +26.34% | 37.42B | |
| -0.71% | -3.69% | +20.76% | +39.59% | 31.03B | |
| -2.43% | +1.38% | +198.54% | +339.30% | 23.25B | |
| -1.16% | +2.67% | +81.09% | +167.21% | 17.21B | |
| Average | -1.09% | -0.81% | +59.59% | +85.15% | 28.45B | |
| Weighted average by Cap. | -1.03% | -0.13% | +49.39% | +69.69% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 222M 276M 238M 206M 384M 25.05B 413M 2.55B 1B 11.95B 1.04B 1.01B 43.62B | 254M 317M 273M 237M 441M 28.76B 474M 2.93B 1.15B 13.72B 1.19B 1.16B 50.1B |
| Net income | 39.81M 49.61M 42.77M 37.06M 69.01M 4.5B 74.25M 458M 181M 2.15B 186M 182M 7.84B | 55.25M 68.85M 59.35M 51.44M 95.77M 6.25B 103M 636M 251M 2.98B 258M 253M 10.88B |
| Net Debt | -73.61M -91.72M -79.08M -68.53M -128M -8.32B -137M -847M -334M -3.97B -344M -337M -14.5B | -133M -165M -143M -124M -230M -15.01B -248M -1.53B -602M -7.16B -620M -607M -26.14B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 54.20 CHF | -0.91% | 33,372 |
| 15/01/26 | 54.70 CHF | -3.36% | 28,882 |
| 14/01/26 | 56.60 CHF | +4.62% | 35,804 |
| 13/01/26 | 54.10 CHF | -2.35% | 56,775 |
| 12/01/26 | 55.40 CHF | -4.48% | 37,065 |
Delayed Quote Swiss Exchange, January 16, 2026 at 04:31 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition